Cargando…
Bortezomib treatment for severe refractory anti‐NMDA receptor encephalitis
OBJECTIVE: To evaluate the therapeutic potential of bortezomib, a proteasome inhibitor that target plasma cells, in order to revive stalled recovery in patients with anti‐N‐methyl‐d‐aspartate (NMDA) receptor encephalitis who remain bedridden even after aggressive immunotherapy. METHODS: We consecuti...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945964/ https://www.ncbi.nlm.nih.gov/pubmed/29761122 http://dx.doi.org/10.1002/acn3.557 |